Patent intelligence · US
US 10925961
Vaccines with CD40 ligand as an adjuvant
Vaccines with CD40 ligand as an adjuvant
Patent details — US 10925961
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 23, 2021
- Expiration
- Feb 18, 2041
- Applicant
- Inovio Pharmaceuticals, Inc.
- Claims
- 18
- CPC classes
- A61K, A61K2039/53, A61K2039/55516, A61K2039/585
Quick answer
US 10925961 (Vaccines with CD40 ligand as an adjuvant) is held by Inovio Pharmaceuticals, Inc.. Status: granted. Granted Feb 23, 2021. Expires Feb 18, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Inovio Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K2039/53, A61K2039/55516, A61K2039/585, A61K39/0011, A61K39/12
More from Inovio Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12285473
Cancer vaccines targeting MUC16 and uses thereof
granted -
US 12280108
Vaccines having an antigen and interleukin-21 as an adjuvant
granted -
US 12251561
Minimally invasive dermal electroporation device
granted -
US 12240872
Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
granted -
US 12161706
Cancer vaccines targeting BORIS and uses thereof
granted -
US 12109258
Synthetic malaria immunogens, combinations thereof, and their use to prevent and treat malaria infections
granted -
US 12064473
Cancer vaccines targeting Survivin and uses thereof
granted -
US 12054537
Optimized nucleic acid antibody constructs encoding anti-respiratory syncytial virus (RSV) antibodies
granted
Frequently asked questions
What is US patent 10925961?
US 10925961 (Vaccines with CD40 ligand as an adjuvant) is held by Inovio Pharmaceuticals, Inc.. Status: granted. Granted Feb 23, 2021. Expires Feb 18, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10925961?
Inovio Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 75 pharmaceutical patents for this assignee.
When does US 10925961 expire?
Our index shows an expiration date of Feb 18, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.